We are excited to announce that SynCore Biotechnology receives Investigational New Drug (IND) clearance of SB05 (EndoTAG®-1) by the French National Agency for Drugs and Health Food Safety (ANSM) to conduct a Phase III Clinical Trial for the treatment of metastatic adenocarcinoma of the Pancreas. The trial is anticipated to be completed by the fourth quarter of the year 2020.
About SynCore Biotechnology Co., Ltd
SynCore Biotechnology Co., Ltd (“SynCore”) is a biopharmaceutical company focusing on creating values of new drugs by R&D and integration of technology resources. SynCore was established in 2008 and cofounded by Sinphar Group and National Health Research Institute (NHRI). SynCore utilizes and in-licenses the unique technologies from all over the world to develop new drugs for unmet medical needs with great marketing potential. Syncore’s comprehensive pipeline portfolio of new drugs in the area of oncology, ophthalmology, dermatology and infectious diseases.
Meet us at:
– CBIIC, China, Sep. 2018
– Bio Partnering APAC, China, Sep. 2018
– Bio Europe, Denmark, Nov. 2018